Tirzepatide (Mounjaro) is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist which appears more active towards GIP than GLP-1, which may have beneficial implications.
“Tirzepatide selectively engages cAMP signaling over β-arrestin recruitment at the GLP-1R may be of fundamental importance that beneficially impacts GLP-1R trafficking, thus augmenting cellular response. Indeed, others have reported that GLP-1R agonists possessing similar signaling bias are more effective than matched, unbiased agonists at controlling glucose and body weight in mice”
Dr Bob, Brain Mechanic 